Wellspring Blog

2017 USPTO stats show a slight increase in patent grants compared to 2016. However, fewer patent applications are being published. Why? These numbers illustrate a shift in mindset towards patent applications among intellectual property (IP) teams that has appeared in recent years. Read More

Employ Technology Scouting and IP Management For many industries, innovation is a slow and costly process. This is especially true of capital-intensive verticals such as chemical manufacturing. Yet, innovation remains a top priority for corporate bosses in the chemical industry and a major... Read More

5 Tips for Successful Industrial Research Partnerships Read More

The SRA International Annual Meeting was a tremendous event for networking and education. I had the opportunity to speak at the SRA talks to discuss what’s wrong with sponsored research administration and what you need to address these challenges. The following blog summarizes my presentation. Read More

“You Need an Innovation Strategy” is the title of a recent article in the Harvard Business Review; it is also a statement of fact. An organization without one is, as author Gary Pisano notes, a “grab bag of much-touted best practices” that will only become successful through sheer luck. Pisano put... Read More

Read More

For more than 40 years, AUTM has provided essential education for technology transfer professionals around the world. The annual AUTM event continues to serve as the single most important meeting place for industry leaders, investors, and academic research professionals. Read More

Few people can start a buzz quite like Elon Musk. Even his cars get people to stop and stare as they drive down the street. Me? I actually offered a guy at my gym money if he’d let me drive his Model S around the block. (He declined. Turns out if you spend $70,000 on a car, you’re not willing to... Read More

Pfizer and the NIH have taken sides on who owns background intellectual property (IP) rights to the blockbuster arthritis drug Xeljanz. Its undisputed that Pfizer invested over $1B in the drug, and its undisputed that Pfizer and NIH had an joint R&D contract, called a CRADA, in place during the... Read More